Clearside biomedical, inc. (CLSD)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating activities
Net loss

-2,911

-3,096

-6,536

-5,734

-15,404

-21,638

-23,872

-20,701

-16,607

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-18,336

-13,773

-10,373

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

45

51

53

54

53

48

47

47

47

47

48

57

30

Share-based compensation expense

1,001

1,139

970

1,256

1,247

1,162

1,286

1,199

1,138

944

889

779

752

Non-cash interest expense

10

22

48

47

46

47

47

11

49

52

54

53

52

Accretion of debt discount

21

21

15

16

15

17

16

30

49

54

53

52

53

Amortization and accretion on available-for-sale investments, net

-

0

0

12

103

234

270

201

43

37

24

-12

-18

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-49

1,129

-224

1,189

-1,536

-1,181

856

217

613

708

-114

-2,066

2,305

Other assets and liabilities

-68

-

-

-

29

-

-

-

-

-

-

-

-

Other assets and liabilities

-

-

-

-

-

-

-

62

-12

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

13

-14

62

Accounts payable and accrued liabilities

-1,086

83

-963

-4,688

-14

-4,868

3,914

299

341

1,021

3,708

-886

872

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-5

-5

-5

Deferred rent

-

-

-

-

-

-

-

-

-26

-

51

80

-10

Net cash used in operating activities

-2,803

1,689

-6,047

-10,057

-12,653

-24,259

-19,719

-19,569

-15,653

-

-

-

-

Investing activities
Maturities of available-for-sale investments

-

0

0

2,000

30,950

16,500

28,100

10,900

20,970

15,461

28,072

18,035

6,975

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-10,978

Purchase of available-for-sale investments

-

-

-

-

-

-

-

-

8,725

-

15,011

12,947

12,656

Acquisition of property and equipment

55

0

0

7

18

-

-

-

-

0

-13

10

309

Net cash (used in) provided by investing activities

-55

0

0

1,993

30,932

16,441

375

-32,821

12,245

-

-

-

-

Financing activities
Proceeds from at-the-market sales agreement, net of issuance costs

1,193

-

-

-

6,627

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-5,990

Proceeds from follow-on public offering, net of issuance costs

-

-

-

-

-

-

0

0

79,581

-

0

0

5,057

Proceeds from exercise of stock options

-

1

5

0

1

32

0

196

237

43

1

119

76

Principal payments made on long-term debt

-

-

-

-

-

0

0

7,500

800

-

-

-

-

Net cash provided by financing activities

1,193

-1,645

2,424

1,288

6,628

20

0

2,741

79,018

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

5,133

Net (decrease) increase in cash, cash equivalents and restricted cash

-1,665

44

-3,623

-6,776

24,907

-7,798

-19,344

-49,649

75,610

-7,065

-386

-6,314

-11,835

Supplemental disclosure
Tenant improvements paid by landlord

-

-

-

-

-

-

-

-

-

0

0

0

637